Literature DB >> 31092418

11Boron Delivery Agents for Boron Proton-capture Enhanced Proton Therapy.

Katalin Hideghéty1,2, Szilvia Brunner3, Andrew Cheesman1, Emilia Rita Szabó1, Róbert Polanek1, Daniele Margarone4, Tünde Tőkés1, Károly Mogyorósi1.   

Abstract

The aim of this review was to define appropriate 11B delivery agents for boron proton-capture enhanced proton therapy (BPCEPT) taking into account the accumulated knowledge on boron compounds used for boron neutron capture therapy (BNCT). BPCEPT is a promising treatment approach which uses a high linear energy transfer (LET) dose component in conjunction with conventional proton therapy to increase the relative biological effectiveness of highly-selective charged particle therapy. Boron proton fusion reactions occur with highest cross section at certain proton energy level and thus can be tailored to the target volume with careful treatment planning that defines the 675 MeV proton distribution with high accuracy. Appropriate 11B compounds are required in order to achieve relevant high LET dose contribution from the boron proton-capture reaction. Previous scientific results and experiences with BNCT provide background knowledge and information regarding the optimization of boronated compound development, their characterization, measurement and imaging. However, there are substantial differences between BNCT and BPCEPT, which in turn places special unique chemical, physical and biological demands on 11B-carrier compounds for BPCEPT. In this review, we evaluate well-known and recently developed boron compounds for BPCEPT. Copyright
© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  BNCT; Boron delivery agents; boron-neutron capture therapy; boron-proton capture enhanced proton therapy BPCEPT; review

Mesh:

Substances:

Year:  2019        PMID: 31092418     DOI: 10.21873/anticanres.13343

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Cold Physical Plasma Decreases the Viability of Lung Adenocarcinoma Cells.

Authors:  E A Golubitskaya; O S Troitskaya; E V Yelak; P P Gugin; V A Richter; I V Schweigert; D E Zakrevsky; O A Koval
Journal:  Acta Naturae       Date:  2019 Jul-Sep       Impact factor: 1.845

2.  Smart material based on boron crosslinked polymers with potential applications in cancer radiation therapy.

Authors:  José Vedelago; Marcelo Romero; Facundo Mattea; Sebastián Triviño; María Del Mar Montesinos; Walter Keil; Mauro Valente
Journal:  Sci Rep       Date:  2021-06-10       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.